Last reviewed · How we verify
Bupivacaine-adrenaline
Bupivacaine is a local anesthetic that blocks sodium channels in nerve fibers, while adrenaline (epinephrine) causes vasoconstriction to prolong anesthetic duration and reduce systemic toxicity.
Bupivacaine is a local anesthetic that blocks sodium channels in nerve fibers, while adrenaline (epinephrine) causes vasoconstriction to prolong anesthetic duration and reduce systemic toxicity. Used for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks.
At a glance
| Generic name | Bupivacaine-adrenaline |
|---|---|
| Also known as | Marcain-adrenalin |
| Sponsor | University of Aarhus |
| Drug class | Local anesthetic with vasopressor |
| Target | Voltage-gated sodium channels; alpha-1 adrenergic receptors (adrenaline component) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Pain Management |
| Phase | FDA-approved |
Mechanism of action
Bupivacaine penetrates nerve cell membranes and reversibly inhibits sodium influx, preventing depolarization and action potential propagation in sensory and motor nerves. The addition of adrenaline causes local vasoconstriction, which slows systemic absorption of the anesthetic, extends its duration of action, and reduces peak plasma concentrations and associated toxicity risks.
Approved indications
- Local and regional anesthesia for surgical procedures
- Infiltration anesthesia
- Nerve blocks
- Epidural and spinal anesthesia
Common side effects
- Transient neurological symptoms (TNS)
- Hypotension
- Bradycardia
- Headache
- Nausea
- Systemic toxicity (CNS and cardiac)
Key clinical trials
- mTLIP vs QIPB for Postoperative Analgesia in Lumbar Microdiscectomy Surgery (NA)
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block (NA)
- Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition (PHASE4)
- Postop Pain Management in Pituitary Tumour Patients (PHASE4)
- Multifidus Plane Block Versus Caudal Block for Hypospadias (NA)
- Sacral ESPB vs. PENG Block for Hip Hemiarthroplasty Analgesia (NA)
- Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine-adrenaline CI brief — competitive landscape report
- Bupivacaine-adrenaline updates RSS · CI watch RSS
- University of Aarhus portfolio CI